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Abstract
Objectives
To evaluate urokinase plasminogen activator (u-PA), urokinase plasminogen activator soluble receptor (su-PAR), 
plasminogen activator inhibitor I (PAI-1) and tissue plasminogen activator (t-PA) plasma levels in SSc patients (pts) versus
healthy controls and their modulation by intravenous alphacyclodestrine (Alprostadil). 
Methods
Plasma levels of u-PA, su-PAR, PAI-1 and t-PAwere measured in 40 SSc (34 lSSc and 6 dSSc) pts and in 30 healthy controls.
In SSc, blood was drawn before and after 3 consecutive daily of Alprostadil infusion (60 mg in 250 cc NaCl 0.9%).
Results
In SSc su-PAR basal levels were higher than controls (7.48 ± 2.5 vs 4.69 ± 0.4 ng/ml; p = 0.001) and were significantly
reduced by Alprostadil (5.93 ± 1.7; p = 0.002), but remain higher than controls (p = 0.03). u-PAbasal levels were higher
than controls (3.78 ± 1.5 vs 1.29 ± 0.3 ng/ml; p < 0.001) and were reduced by Alprostadil (2.39 ± 1.7; p < 0.001) to control
levels. SSc PAI-1 basal levels were lower than controls (31.60 ± 7.7 vs 48.30 ± 6.8 ng/ml; p < 0.001) and increased by
Alprostadil (34.66 ± 5.4; p = 0.04), but lower than controls (p < 0.001). SSc  t-PAbasal levels were higher in respect to 
controls (1645.81 ± 792.7 vs 571.95 ± 75.5 pg/ml; p < 0.0001) and reduced by Alprostadil (1318.06 ± 603.5; p = 0.04), 
but still higher than controls (p = 0.001). 
Conclusion
Fibrinolysis were increased in SSc. Infusions of Alprostadil modulate u-PA, su-PAR, PAI-1 and t-PA, restoring near normal
levels. In SSc, fibrinolysis system may become a potential target for new therapies.
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Introduction
Systemic sclerosis (SSc) is a connec-
tive tissue disease of unknown aetiolo-
gy, characterized by microvascular in-
volvement, immune alteration and fi-
brosis of the skin and internal organs.
In SSc, microvessel abnormalities are
characterized by thickening of the inti-
ma, thinning of the media, fibrosis of
the adventitia and occlusion of vascular
lumen (1), due to enhanced thrombus
formation and extensive fibrin deposi-
tion. 
In SSc, the pathway leading to fibrin
deposition is not well understood, but
several studies suggest that coagulation
system is activated, as shown by in-
creases of T h r o m b i n - A n t i t h r o m b i n
(TAT) complexes, prothrombin releas-
es fragment 1+2 (F 1+2), and D-dimers
circulating levels (2-4). Likewise, con-
troversial issues concern the fibrinolyt-
ic activity in SSc. Several studies have
reported both depressed basal (5, 6)
and activated fibrinolytic activity (7),
while others have shown normal fibri-
nolytic activity (8, 9) and normal tissue
plasminogen activator (t-PA) concen-
trations in skin and plasma (10).  
Alprostadil, an analogue of Prostaglan-
din E1 (PGE1) with potent vasodilating
actions, has been successfully employ-
ed by intravenous infusions in several
diseases for the treatment of chronic
critical limb ischemia (11) and, in SSc,
for the treatment of Raynaud phenome-
non (RP) (12) and for the control of fin-
gertips and lower limbs ulcers. T h e
increase of peripheral blood flow ob-
served after intravenous A l p r o s t a d i l
may be explained not only by its vaso-
dilating actions, but also by inhibition
of platelet adhesion and aggregation
and modulation of neutrophil activa-
tion (13). 
In patients with RPsecondary to SSc,
intravenous infusions of A l p r o s t a d i l
improve endothelial cells (EC) func-
tion as indicated by the decrease of
plasma levels of tissue plasminogen
activator (t-PA), von Willebrand factor
(vWF), and Intercellular A d h e s i o n
Molecule 1 (ICAM-1) (14). 
On the basis of these considerations,
we attempted to evaluate the levels of
components of fibrinolytic system in
patients with SSc and their acute mod-
ulation by an intravenous infusion of
Alprostadil.
Therefore, molecule markers of the fib-
rinolytic system such as tPA, PAI-1, by
urokinase plasminogen activator (u-
PA) and its soluble receptor, the uroki-
n s  plasminogen activator eceptor
( s u - PAR), that regulate xtra cellular
pr teolysis, chemotaxis, cell attach-
ment, proliferation, differentiation and
fibrin degradation (15) were deter-
mined before and after 3 consecutive
days of Alprostadil treatment.
Patients and methods 
P e ts
Forty consecutive Caucasian SSc pa-
tie ts (38 females and 2 males; mean
age: 60.6± 9.3 years), attending the
section of Rheumatology of the Uni-
versity of Florence, and of the Depart-
ments of Medicine of University of
Ancona and L’Aquila, were enrolled in
the study. Thirty healthy subjects,
matched for sex and age with the pa-
tients, served as controls. The local eth-
cal committee approved the study and
a written informed consent was obtain-
ed from both patients and healthy con-
trols. Patients were classified in limited
SSc and diffuse SSc according to Le
Roy et al. (16).
Exclusion criteria were: age < 18 years,
pregnancy, stroke in the 4 months pre-
ceding the study, myocardial ischemia,
heart failure, systemic arterial hyper-
te sion not pharmacologically con-
trolled, thrombocytopenia (platelet
c unt < 100,000/1012 L), thrombocyto-
sis (platelet count > 500,000/1012 L),
renal failure, chronic hepatitis, diabetes
mellitus and malignancy. 
SSc patients treated with drugs poten-
tially able to modify the evolution of
the disease (corticosteroids, methotrex-
ate, cyclophosphamide, D-penicilla-
mine, iloprost) were excluded as well as
patients whose conditions did not allow
a complete pharmacological wash-out
(patients with severe ulcers, severe ar-
tery pulmonary hypertension, severe
respiratory failure, congestive heart
failure III–IV class of NYHA, creati-
ni e values ‡ 1.5 mg/dl and mega-
oesophagus and/or malabsorption).
All SSc patients were under treatment
with topical gliceril nitrate, ACE inhi-
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bitors, calcium channel blockers, pro-
ton pump inhibitors and clebopride.
Before sampling, patients were washed
out for 10 days from oral and topics
vasodilators.  
The SSc patients were evaluated for
disease duration, calculated from the
onset of the first non-Raynaud’s symp-
tom, (17) and assessed for microvascu-
lar, skin and organ involvement by a
careful workout.
Analyses
Skin and microvascular involvement.
At the time of blood drawing, the pres-
ence of fingertip ulcers, other skin
ulcers (e.g. at heels, legs, elbows, fore-
arms), calcinosis, teleangectasias, and
Raynaud’s phenomenon was recorded.
Skin involvement was assessed and
scored with the modified Rodnan skin
score (18). The small vessel architec-
ture was studied by nailfold videocapil-
laroscopy (NVC) and patients divided
into three groups as follow according
to Cutolo et al. criteria in early (14
patients), active (14 patients) and late
(12 patients) (19).
C a rdiovascular involvement. Two di-
mensional ultrasound evaluation and
standard EKG assessed cardiovascular
involvement Arterial blood pressure
was recorded (1).
Lung involvement. Lung involvement
was evaluated by forced vital capacity
(FVC), diffusing lung capacity for car-
bon monoxide (Dlco), and high resolu-
tion computed tomography (HRCT) 
Kidney involvement. Kidney involve-
ment was evaluated by renal function
tests (including 24-h creatinine clear-
ance) 
Autoantibodies. Antinuclear antibodies
(ANA) (by indirect immunofluores-
cence on rat liver), anticentromere anti-
bodies (ACA) [by indirect immunoflu-
orescence on Hep-2 cells and by En-
zyme-linked immunoabsorbent assay
(ELISA) for CENPantigen)] and anti-
topoisomerase I antibodies (anti-Scl70)
(by immunoblot analysis), Rheumatoid
Factor (RF) (by ELISA) were deter-
mined.
Assessment of fibrinolytic system 
components
In SSc patients, blood was drawn, be-
fo e infusions and after 3 consecutive
daily infusions (60 g in 250 cc of phys-
iological solution in 3 hours) of A l-
pro tadil (Alprostadil–Leiclodedrin®,
Schwarz Pharm). 
After drawing, blood samples were col-
lected in vacutainers containing EDTA
(1 mg/ml), maintained in ice for 30-60
min tes, centrifuged (5000 g for 15
minutes) at 4°C to obtain plasma and
conserved at -80° C, until assayed. 
u - PA (ng/ml), su-PAR (ng/ml), PA I- 1
(ng/ml) and t-PA(pg/ml) plasma levels
were determined by ELISAkits (kits
ovided by IMUBIND American Di-
agnostica, Montreal, Canada). The re-
sults were correlated to a standard
curve, within the range of linearity.
Each sample was evaluated in tripli-
cate and with two different dilutions.
The sensibility levels were: 10 pg of
u PA/ml of sample; 0.1 ng of uPA R / m l
of sample; 1 ng of PAI-1 /ml of sam-
ple. tPAplasma (pg/mL) levels were
determined by ELISAkits (kit provid-
ed by Bender MedSystems, Vi e n n a ,
Austria) The sensibility levels were 16
p g / m l .
Statistics
Data were analysed using SPSS 10.0
for Windows. Descriptive statistics
w re expressed as mean ± standard
deviations (SD). 
Normal distribution of each examined
parameter was verified by Kolmogo-
rov-Smirnoff test. The statistical signif-
icance of the differences between means
of two groups was evaluated by the
Student’s t-test for paired or unpaired
Table I.Anthropometric and clinical characteristic of SSc patients and healthy controls.
SSc Healthy controls
(40 patients) (30 subjects)
Age (years) 60.6± 9.3 56.20± 11.4
Height (cm) 159.7± 7.0 164.2 ± 5.2
Weight (kg) 62.50±13.0 64.8 ±15.2
BMI 24.1± 3.9 26.3 ± 5.4





Disease duration (years) 8.8 ± 7.6
Skin score 12.7±10.2
Skin ulcers + 6/40












DLCO (%) 63.6 ±23.0
Lung HRCT + 19/38
Heart involvement + 15/38
BMI: body mass index(weight in Kg/ height in m2; lSSc: limited SSc; dSSc: diffuse SSc; R.P. Raynaud
Phenomenon; ANA: antinuclear antibodies; Scl70: anti-Scl70 antibodies; ACA: anticentromere anti-
bodies; auto-Ab-: negativity for autoantibodies; RF: rheumatoid factor; FVC: forced ventilatory capac-
ity; DLCO: diffusing lung capacity for carbon monoxide HRCT: high resolution computed tomography.
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data and, when indicated, by the Wil-
coxon’s signed-rank test (paired data)
or the U-test of Mann-Whitney (un-
paired data). 
The statistical significance of the dif-
ferences between means of more than
two groups was evaluated by ANOVA
with Bonferroni correction test and
Kruskal Wallis test when indicated. 
Non-parametric and parametric corre-
lation analyses were performed with
the Spearman’s rank correlation test
and Pearson test, respectively. 
A p level of 0.05 or less was considered
statistically significant.
Results
Demographic and clinical features of
SSc patients (34 lSSc and 6 dSSc) are
reported in Table I. 
Baseline plasma levels of u-PA, 
su-PAR, t-PAand PAI-1 (Table II 
and Fig. 1)
The circulating plasma levels of u-PA,
su-PAR, PAI-1 and t-PA in SSc, in d-
SSc, lSSc and controls are shown in Ta-
ble II. 
u - PA basal concentrations (3.78±1 . 5
ng/mL) were significantly higher in
SSc than in controls (1.29 ± 0.3; p <
0.0001) and both in lSSc (3.41 ± 1.15)
and dSSc (5.83 ± 0.68) than in controls
(p < 0.0001). u-PA levels were signifi-
cantly higher in dSSc than in lSSc (p <
0.0001). 
su-PAR basal levels were higher (7.48
± 2.5 ng/mL) in SSc (p<0.001) and in
lSSc (7.54 ± 2.48; p<0.005) than con-
trols (4.69 ± 0.4), but non in dSSc (7.18
± 2.98). No difference was detected
be ween lSSc and dSSc. 
t-PA plasma levels were significantly
higher in SSc (1654.8 ± 792.7 pg/mL)
and in lSSc (1714.5 ± 809.5) than con-
trols (571.9±75.5) (p<0.0001), but not
in dSSc levels (1256.3±602.3). No dif-
ference was present between lSSc and
dSSc. 
PAI-1 levels (31.6±7.7 ng/mL) were
significantly lower in SSc patients (p <
0.0001) and both in dSSc (27.15 ±
8.29) and in lSSc (32.33 ± 7.48) versus
controls (48.3 ± 6.85; p < 0.0001). No
difference was found between lSSc and
dSSc. 
Plasma levels of u-PA, su-PAR, t-PA
and PAI-1 after Alprostadil (Table II
and Fig. 1)
In SSc patients, u-PA plasma levels
were reduced after Alprostadil (2.39 ±
1.73 after) in respect to basal values
(3.78 ± 1.5; p < 0.001), reaching values
not different from those of controls
(1.29 ± 0.3). 
Alprostadil reduced u-PA plasma levels
both in lSSc (3.41 ± 1.15 before vs 1.89
± 0.21 after; p<0.0001) and in dSSc
(5.83 ± 1.8 before vs 5.05 ± 0.68 after;
p < 0.01), reaching control levels (1.29
±0.3; p<0.0001) in lSSc but not in dSSc. 
su-PAR plasma levels were reduced by
Alprostadil (7.48 ± 2.5 before vs 5.93 ±
1.78 after; p<0.01), but remained high-
er than in controls (4.69±0.4; p< 0.05),
while, both in lSSc and in dSSc, su-
PAR levels (5.51±0.28 and 6.42± .66,
respectively) were reduced in respect
to baseline (7.54±2.48; p< 0.0001 and
7.18±2.98; p<0.05, respectively). 
t-PA levels were reduced by Alprostadil
( 1 6 4 5 . 8±792.7 before vs 1318.06±
603.55 after; p<0.05), but remained sig-
nificantly higher than controls (571.9±
75.5; p<0.001). Alprostadil reduced sig-
nificantly t-PA levels in lSSc (1714.5 ±
809.5 before vs 1360.26 ± 627.72 after;
p<0.0001), which however were high-
er than controls (571.9±75.5; p<0 . 0 1 ) .
In dSSc, t-PAlevels did not change.
Alprostadil increased PAI-1 levels
(31.6 ± 7.7 before vs 34.66 ± 5.4 after p
< 0.05), which remained still lower
than controls (48.3 ± 6.85; p < 0.0001),
and did not modify PAI-1 levels neither
in lSSc nor in dSSc.
C o relations of u-PA, su-PAR, t-PAa n d
PAI-1 levels with clinical features 
u-PA levels were significantly lower in
SSc patients with teleangectasias (mean
3.4 ± 0.2 ng/ml) than in patients with-
out (4.6 ± 0.4 ng/ml, p < 0.02) and cor-
related with skin score (r = 0.3532; p <
0.05). 
PAI-1 levels resulted significantly low-
er in patients without than in those with
fingertips ulcers. 
No other significant correlation of u-
PA, su-PAR, t-PA and PAI-1 levels with
age, disease duration, ulcers, lung,
heart kidney involvement and autoanti-
bodies pattern was found.
Discussion
The role of fibrinolytic system in the
pathogenesis of micro-vessel injury in
SSc is still a matter of debate, since
many studies have shown discordant
Table II.Circulating levels of fibrinolytic system components in SSc, dSSc, lSSc and controls. Laterally, effects of Alprostadil: levels of
significantly in SSc before and after PGE1 therapy.
Pts  N° u-PA(ng/mL) su-PAR (ng/mL) t-PA(pg/mL) PAI-1 (ng/mL)
SSc 40 Before 3.78 ± 1.5 *** 7.48 ± 2.5 ** 1645.8 ± 792.7*** 31.6 ± 7.7***
After ** 2.39 ± 1.73 * 5.93 ± 1.78* * 1318.06± 603.55** • 34.66± 5.4***
lSSc 34 Before 3.41 ± 1.15*** 7.54 ± 2.48* 1714.5 ± 809.5*** 32.33± 7.48*** ns
After *** 1.89 ± 0.21 ns *** 5.51 ± 0.28 ns *** 1360.2 ± 627.72* ns 33.93± 4.96***
dSSc 6 Before 5.83 ± 1.8*** 7.18 ± 2.98 ns 1256.3 ± 602.3 ns 27.15± 8.29***
After * 5.05 ± 0.68*** • 6.42 ± 2.66 ns ns 1092 ± 424.7 ns ns 38.58± 6.42***
Controls 20 1.29 ± 0.3 4.69 ± 0.4 571.9 ± 75.5 48.3 ± 6.85
***:p < 0.0001;    **:p < 0.001;   *:p < 0.01;   • : p < 0.05;   Ns: not significative.
results. An activation of the fibrinolytic
system in SSc, characterized by increase
of tPA(14, 20) and D-dimers  (21, 22)
or by reduction of inhibitors such as
a 2-antiplasmin, has been reported (23).
Instead, a reduction of some fibrinolyt-
ic components such as tPA and uPA
(23, 24) or an increase of PAI-1 levels
(2, 25, 26) has been shown by other au-
thors. Other studies reported both acti-
vation and depression of the fibrinolyt-
ic system with increase of t-PA a n d
PAI-1 concentrations (27) or increased
levels of some fibrinolytic components
associated to a reduction of fibrin de-
gradation products (D-dimers) (4).
Herrick et al. (8) found no significant
variation of PAI-1 and t-PA levels in
patients with SSc. All these discrepant
findings show the difficulty in defining
the changes of the fibrinolytic system
in SSc. 
In our patients, before Alprostadil treat-
ment, the fibrinolytic system seems ac-
tivated and not down regulated. How-
ever,Alprostadil infusion induces a sig-
nificant decrease of t-PA, u-PA and su-
PAR levels and a significant increase of
PAI-1 concentrations, indicating a
blunting of the fibrinolytic activity. 
Since SSc is characterized by wide-
spread fibrin deposit, the down-regula-
tion of fibrinolysis just after the Al-
prostadil infusion might be considered
an unfavourable drug effect. Neverthe-
less, a bulk of evidence indicates that
Alprostadil, in SSc patients, signifi-
cantly reduces the frequency of RP
attacks and reduces the levels of endo-
thelial cell damage markers (28-31,
14). 
Fibrinolysis is primarily a function of
the endothelium and circulating levels
of tPA u - PA, su-PAR and PAI-1 are
considered a surrogate markers of en-
dothelial derangement. tPA is an en-
dothelial product that increases when
endothelium is damaged or activated
(32).
During the formation of a blood clot af-
ter injury to a blood vessel, fibrinogen
is converted into fibrin, where its main
function is to strengthen the clot. Ex-
cessive fibrin deposition is prevented
by the fibrinolytic system through plas-
min function, which is responsible for
the removal of inappropriately formed
fibrin. Plasmin is produced, where re-
quired, by cleavage of its inactive pre-
c u r s o r, plasminogen, and the rate of
this cleavage is driven by the relative
proportion of activators and inhibitors
of fibrinolysis.
Our data suggest that all components of
fibrinolytic system are activated in SSc
patients, as indicated by the increased
plasma concentrations of u-PA, su-
PAR, and t-PA and by the reduced con-
centrations of PAI-1. In SSc the activa-
tion of fibrinolysis may reflect and fol-
low an enhance coagulation cascade
suggested by increased levels of vWF,
(32,8) fibrinogen, (33), F1-2 frag-
ments, D-dimers and TAT complexes
(2-4). Furthermore, at the best of our
knowledge, no study supports a prima-
ry activation of fibrinolytic system in
SSc. From this point of view, the en-
hanced fibrinolysis observed in our
SSc patients may be explained as an
attempt to limit the engulfment of the
micro vessels with fibrin and, eventual-
ly, their occlusion. Interestingly, chron-
ic thrombin generation and intra-ves-
sels fibrin deposition may have conse-
quences beyond their haemostatic role.
Thrombin may enhanced fibroblast
replication and chemotaxis (34,35) and
may favour the synthesis and release
endothelin-1, a vasoconstrictive and
p ofibrotic peptide, that play a pivotal
role in the pathogenesis of SSc. In
close relationship with thrombin, fibrin
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Fig. 1.tPA (pg/mL) (A) and uPA, suPAr
and PAI levels (ng/L) (B) before and
after PGE1 therapy.
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may induce vWF release from endothe-
lial cells (36) and may promote fibrob-
last proliferation and chemotaxis (37).
In our SSc patients, Alprostadil e-
crease t-PA and su-PAR levels, restore
normal u-PA levels and increase PAI-1
levels. This suggests a positive action
of the drug on the endothelial injury re-
ducing the imbalance of the homeosta-
sis between the procoagulant and fibri-
nolytic properties of endothelial cells
(1). 
The protective action of Alprostadil on
the endothelium may acts through dif-
ferent pathways, like the protection
against the reperfusion injury, the dam-
age of reactive oxygen species, the
protease neutrophil cytotoxicity, and
by the inhibition of leukocyte adher-
ence to endothelium (38). A l p r o s t a d i l
modulates haemostatic and fibrinolytic
parameters. In patients with intermit-
tent claudicatio, it reduces thrombin
formation and fibrin degradation, de-
creasing plasma levels of all haemosta-
tic and fibrinolytic parameters (13).
M o r e o v e r, Alprostadil significant de-
creased the tPAplasma levels in SSc
patients (14) at the same doses used in
our patients but with different time
schedule (infusion was repeated on 5
consecutive days, 3 times at 6 week in-
tervals during the winter months). Our
data shows also an increased concen-
tration of su-PAR, usually found in pa-
tients with various forms of malignan-
cies (39-43) or severe form of infec-
tions (44-47). suPAR is derived from
proteolytic cleavage of uPAR from the
cell surfaces by a number of proteases,
such as chymotrypsin (48), phospholi-
pase C (49) and uPA(50). uPAR is ex-
pressed on different cell types, includ-
ing neutrophils, lymphocytes, macro-
phages, endothelial and malignant cells
and with its ligand, uPA, is involved in
numerous biological functions. In the
pathogenesis of cancer, uPAand uPA R
play a key role in tissue invasion by
converting plasminogen into plasmin,
leading to the degradation of extracel-
lular matrix (51). Moreover uPAR is
able to bind b -integrins (52), promot-
ing the migration of leukocytes (53).
Proteolytic cleavage of uPAR from the
cell surface can release an active che-
motactic form of suPAR (54,55). Inter-
l e u k i n - 1b , basic fibroblast growth fac-
tor or vascular endothelial growth fac-
tor increase suPAR release from endo-
thelial cells, whereas platelet derived
growth factor-BB, bFGF or IL-1b s t i-
mulate suPAR release from vascular
smooth muscle cells (56). Immune
electron microscopy indicates that, in
atherosclerotic vessels, suPAR may be
found on cell membranes as well as in
the extracellular matrix. These find-
ings may indicate that, in SSc patients,
su PAR from vascular cells is upregu-
lated by fibrinolityc activity, by pro-
angiogenic as well as pro-atherogenic
growth factors and cytokines, and may
be deeply involved in microvascular
a b n o r m alities. 
Although an analysis of the fibrinolytic
variables in different subsets of disease
was not the main purpose of this study,
we found that, after Alprostadil treat-
ment, uPA and, to a lesser extent, su-
PAR plasma levels remained still high-
er in patients with dSSc than in patients
with lSSc (Table II). Whether the in-
creased plasma levels of uPA and su-
PAR may be specific markers of dSSc
or, s mply, may reflect the extension of
the disease in a wide skin area and/or to
internal organs in this subset is, at pre-
sent, unknown. The positive relation-
ship between uPA plasma levels and
th  skin score seems to confirm these
data. However, our results suggest that
the capability of Alprostadil to restore
the endothelium damage and, conse-
quently, to reduce the fibrinolytic activ-
ity is more effective in lSSc than in
dSSc. 
In conclusion, these data indicate that
fibrinolysis is activated in SSc and that
the positive clinical effects of A lp r o-
stadil, affecting several different mech-
anisms, may also lead to a reduction of
fibrinolityc activity. Our results further
support the frequent use of A l p r os t a d i l
in the management of SSc before en-
dothelial damage became irreversible.
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